- Home
- TAK vs DHI Comparison
TAK vs DHI Comparison
Compare TAK & DHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAK | DHI |
|---|---|---|
| Founded | 1781 | 1978 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 45.4B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | TAK | DHI |
|---|---|---|
| Price | $18.55 | $164.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $158.38 |
| AVG Volume (30 Days) | ★ 3.1M | 2.9M |
| Earning Date | 01-01-0001 | 04-21-2026 |
| Dividend Yield | ★ 2.83% | 1.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | N/A | ★ $34,250,400,000.00 |
| Revenue This Year | N/A | $0.32 |
| Revenue Next Year | $0.95 | $6.05 |
| P/E Ratio | ★ $41.25 | $80.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.99 | $110.44 |
| 52 Week High | $18.79 | $183.62 |
Technical Indicators
Market Signals| Indicator | TAK | DHI |
|---|---|---|
| Relative Strength Index (RSI) | 76.26 | 61.08 |
| Support Level | $18.20 | $163.26 |
| Resistance Level | $18.79 | $169.17 |
| Average True Range (ATR) | 0.21 | 5.28 |
| MACD | 0.02 | 0.83 |
| Stochastic Oscillator | 88.72 | 83.91 |
Price Performance
Historical ComparisonAbout TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About DHI D.R. Horton Inc.
With operations in 126 markets across 36 states, D.R. Horton is the leading homebuilder in the United States. It mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.